📰 Statement Regarding News
Page 44 - Statement Regarding News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Statement Regarding. Real-time updates on events, politics, business and more.
January 31, 2023
EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous Defence Therapeutics Inc.: DEFENCE’S LUNG CANCER GLP TOX STUDY ON ITS INTRANASAL ACCUTOXTM FORMULATION ADVANCES 31.01.2023 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. __________________...
January 31, 2023
EQS-News: Defence Therapeutics Inc. / Key word(s): MiscellaneousDefence Therapeutics Inc.: DEFENCE’S LUNG CANCER GLP TOX STUDY ON ITS INTRANASAL ACCUTOXTM FORMULATION ADVANCES 31.01.2023 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement. ______________________________________...
January 31, 2023
Vancouver, British Columbia--(Newsfile Corp. - January 31, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company
January 30, 2023
Our lawyers provide an overview of some of the most significant developments in cybersecurity and data privacy in the United States in 2022 and look ahead to trends for 2023.
January 27, 2023
VANCOUVER, BC / ACCESSWIRE / January 27, 2023 / SILVER X MINING CORP. (TSX-V:AGX)(OTC QB:AGXPF)(F:WPZ) ("Silver X" or the "Company") is pleased to announce their participation at The Metals Investor Forum
January 26, 2023
District Metals Corp. (TSX-V: DMX) (FRA: DFPP); (âDistrictâ or the âCompanyâ) is pleased to note that Swedish media has reported that a majority
January 25, 2023
Consolidated Uranium Inc. (âConsolidated Uraniumâ or the âCompanyâ -
January 24, 2023
Vancouver, British Columbia--(Newsfile Corp. - January 24, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company
January 24, 2023
EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE’S MELANOMA TARGETED VACCINE A1-REPROGRAMMED MSC (ARM) CELL POTENCY VALIDATED 24.01.2023 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement. ________________________________________________________________...
January 24, 2023
EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE’S MELANOMA TARGETED VACCINE A1-REPROGRAMMED MSC (ARM) CELL POTENCY VALIDATED 24.01.2023 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. ____________________________________________...